Becton, Dickinson and Company (BDX)

NYSE: BDX · Real-Time Price · USD

210.02

+3.51 (1.70%)

At close: Feb 6, 2026, 4:00 PM EST

209.02

-1.00 (-0.48%)

Pre-market: Feb 9, 2026, 6:30 AM EST

Revenue Breakdown

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	Sep '19 Sep 30, 2019	Sep '18 Sep 30, 2018	Sep '17 Sep 30, 2017	Sep '16 Sep 30, 2016	Sep '15 Sep 30, 2015	Sep '14 Sep 30, 2014	Sep '13 Sep 30, 2013	Sep '12 Sep 30, 2012
Medication Delivery Solutions Revenue	4.58B	4.43B
Medication Delivery Solutions Revenue Growth	3.30%	3.17%
Medication Management Solutions Revenue	3.47B	3.30B
Medication Management Solutions Revenue Growth	5.37%	10.64%
Pharmaceutical Systems Revenue	2.32B	2.27B
Pharmaceutical Systems Revenue Growth	2.24%	1.97%
Advanced Patient Monitoring Revenue	1.08B	74.00M
Advanced Patient Monitoring Revenue Growth	1362.16%	-
Specimen Management Revenue	1.87B	1.83B
Specimen Management Revenue Growth	2.07%	-
Diagnostic Solusions Revenue	1.84B	1.85B
Diagnostic Solusions Revenue Growth	-0.43%	-
Integrated Diagnostic Solutions Revenue	3.71B	3.68B
Integrated Diagnostic Solutions Revenue Growth	0.81%	1.52%
Biosciences Revenue	1.46B	1.51B
Biosciences Revenue Growth	-3.57%	0.20%
Surgery Revenue	1.57B	1.49B
Surgery Revenue Growth	5.36%	-0.33%
Peripheral Intervention Revenue	2.00B	1.93B
Peripheral Intervention Revenue Growth	3.26%	3.65%
Urology and Critical Care Revenue	1.65B	1.55B
Urology and Critical Care Revenue Growth	6.11%	13.10%
Revenue (Other)	-3.71B	-3.74B
Revenue (Total)	21.84B	20.18B
Revenue (Total) Growth	8.24%	4.16%

Revenue by Geography

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	Sep '19 Sep 30, 2019	Sep '18 Sep 30, 2018	Sep '17 Sep 30, 2017	Sep '16 Sep 30, 2016	Sep '15 Sep 30, 2015	Sep '14 Sep 30, 2014	Sep '13 Sep 30, 2013	Sep '12 Sep 30, 2012
United States Revenue	12.79B	11.66B
United States Revenue Growth	9.66%	4.95%
International Revenue	9.05B	8.52B
International Revenue Growth	6.27%	3.11%
Revenue (Other)	1.00M	-
Revenue (Total)	21.84B	20.18B
Revenue (Total) Growth	8.24%	4.16%

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	Sep '19 Sep 30, 2019	Sep '18 Sep 30, 2018	Sep '17 Sep 30, 2017	Sep '16 Sep 30, 2016	Sep '15 Sep 30, 2015	Sep '14 Sep 30, 2014	Sep '13 Sep 30, 2013	Sep '12 Sep 30, 2012
Medical Revenue	11.46B	10.07B
Medical Revenue Growth	13.72%	6.02%
Life Sciences Revenue	5.17B	5.19B
Life Sciences Revenue Growth	-0.46%	1.13%
Interventional Revenue	5.22B	4.98B
Interventional Revenue Growth	4.76%	5.15%
Revenue (Total)	21.84B	20.18B
Revenue (Total) Growth	8.24%	4.16%

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	Sep '19 Sep 30, 2019	Sep '18 Sep 30, 2018	Sep '17 Sep 30, 2017	Sep '16 Sep 30, 2016	Sep '15 Sep 30, 2015	Sep '14 Sep 30, 2014	Sep '13 Sep 30, 2013	Sep '12 Sep 30, 2012
Medical Segment Operating Income	4.14B	3.58B
Medical Segment Operating Income Growth	15.55%	6.89%
Life Sciences Segment Operating Income	1.64B	1.62B
Life Sciences Segment Operating Income Growth	1.55%	1.06%
Interventional Segment Operating Income	2.25B	2.12B
Interventional Segment Operating Income Growth	6.53%	9.08%
Operating Income (Total)	2.58B	2.40B
Operating Income (Total) Growth	7.59%	13.55%

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	Sep '19 Sep 30, 2019	Sep '18 Sep 30, 2018	Sep '17 Sep 30, 2017	Sep '16 Sep 30, 2016	Sep '15 Sep 30, 2015	Sep '14 Sep 30, 2014	Sep '13 Sep 30, 2013	Sep '12 Sep 30, 2012
Medical Segment Operating Income (Pre-FY2025 Reporting)	-	2.74B
Medical Segment Operating Income (Pre-FY2025 Reporting) Growth	-	39.40%
Life Sciences Segment Operating Income (Pre-FY2025 Reporting)	-	1.60B
Life Sciences Segment Operating Income (Pre-FY2025 Reporting) Growth	-	0.63%
Interventional Segment Operating Income (Pre-FY2025 Reporting)	-	1.42B
Interventional Segment Operating Income (Pre-FY2025 Reporting) Growth	-	16.68%
Operating Income (Total)	2.58B	2.40B
Operating Income (Total) Growth	7.59%	13.55%

Updated Nov 25, 2025. Data Source: Fiscal.ai.